RxDoctor Payments Data

Suzanne Phillips, NP

Family · Killeen, TXNPI 1245532084

Payments from drug & device makers

$935in general payments, 2019–2025

Across 53 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$286
  • Lilly USA, LLC$242
  • Exact Sciences$107
  • Dexcom, Inc.$76
  • Idorsia Pharmaceuticals US Inc$44
  • Amgen$44
  • plus $135 from 5 others

What the payments were for

  • Food & beverage$92199%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$935 in reported general payments places this provider in the 65th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$74,501
Medicare patients
195
Services billed
980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$100,410
MounjaroTirzepatide50$61,573
TrulicityDulaglutide40$42,170
RybelsusSemaglutide16$18,226
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,567
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,371
SymbicortBudesonide/Formoterol Fumarate12$2,681
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,189
Albuterol Sulfate HfaAlbuterol Sulfate97$2,125
Insulin Lispro Kwikpen U-100Insulin Lispro13$1,819
Varenicline Tartrate12$1,209
Pregabalin33$1,138
Diclofenac Sodium37$922
Montelukast Sodium64$888
Atorvastatin Calcium98$846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$286$118,63687 claims
Lilly USA, LLCMounjaro, Trulicity$242$103,74390 claims
GSKTrelegy Ellipta$19$11,56717 claims
AstraZenecaSymbicort$36$2,68112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 15,456 family providers in Texas.

Other family in Killeen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →